Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLR457 in Advanced Solid Malignancies
NCT02189174Phase 1Terminated
- Sponsor
- Novartis
- Start
- Aug 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of CLR457 in solid tumor (advanced stage), sponsored by Novartis. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days and Objective Response Rate. Started Aug 2014; status: terminated.
02
Drugs
CLR457
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02189174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02189174.